Akèy › Karsinòm selil skuamèz tèt ak kou › Massachusetts › Boston
Etid klinik pou Karsinòm selil skuamèz tèt ak kou nan Boston, MA
40 etid pou Karsinòm selil skuamèz tèt ak kou ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Ap rekriteFaz 2/3
- Site #0131, Boston
- Site#0101, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #7, Boston
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Ap rekriteFaz 3
- Boston Medical Center, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
- Research Site, Boston
- Research Site, Boston
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Ap rekriteFaz 3
- Dana Farber Cancer Institute, Boston
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Ap rekriteFaz 3
- Boston Medical Center, Boston
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 1
- Boston Medical Center, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- Tufts Medical Center, Boston
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 2
- Tufts Medical Center, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Ap rekriteFaz 2
- Tufts Medical Center, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Ap rekriteEtid obsèvasyon
- Dana Farber Cancer Institute, Boston
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ap rekriteFaz 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Ap rekriteFaz 2
- Boston Medical Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
PDT For Induction Therapy For Head And Neck Cancer
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- ak 2 plis
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Ap rekriteFaz 1 bonè
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Ap rekriteFaz 1
- Dana Farber/Partners Cancer Care Inc, Boston
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
Ap rekriteEtid obsèvasyon
- Massachusetts Eye and Ear, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Ap rekriteFaz 2
- Dana Farber Cancer Institute, Boston
Etid Karsinòm selil skuamèz tèt ak kou nan lòt vil
- Houston, TX47 etid
- Los Angeles, CA42 etid
- New York City, NY39 etid
- Nashville, TN39 etid
- St. Louis, MO28 etid
- Arlington, VA26 etid
- Philadelphia, PA26 etid
- Chicago, IL26 etid
- Atlanta, GA24 etid
- San Antonio, TX22 etid
- New Haven, CT22 etid
- Pittsburgh, PA22 etid
Lòt etid nan Boston
- Kansè nan tete112 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)85 etid
- Kansè Metastatik63 etid
- Kansè kolorektal63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.